REFILLS
US$ 23.04
astrazeneca glp 1 drug Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds AstraZeneca targets obesity market with
Description
Purpose-built for physicians Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Key takeaways: GLP-1 therapy can provide benefits beyond glycemic control for adults with type 2 diabetes
Exendin-4 antagonizes Abeta1-42-induced attenuation of spatial learning and memory ability
Klausen, M
If injections arent your thing, Rybelsus offers an alternative as the only oral tablet in the GLP-1 category
When treatment is discontinued, weight regain and the deterioration of multiple cardiometabolic risk factors are common
